Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed is an entire field of biotechs working to broaden the reach ...
The FDA approved daraxonrasib, the first targeted therapy for metastatic pancreatic adenocarcinoma, citing a survival benefit vs chemotherapy. The FDA approved daraxonrasib (Rasonque; Revolution ...
Unmanned Surface Vessel Division 12 (Sea Hunter) and 13 (Sea Hunter) conduct unit level training underway in San Diego Bay, California, May 1, 2025. US Navy photo The Navy’s portfolio acquisition ...
b RAS G12, G13 or Q61 mut or no RAS mut identified. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting II. This abstract does not include a full text component.
At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...
Data from the phase 1/2 RMC-6236-001 trial show that the RAS(ON) multiselective inhibitor daraxonrasib yielded responses in pretreated RAS-mutated PDAC. In the phase 1/2 trial, daraxonrasib ...
Add the following CSS to the header block of your HTML document. Then add the mark-up below to the body block of the same document. .videoWrapper { position: relative; padding-bottom: 56.25%; ...
HEC-RAS 6.7 版本中引入的 Pipe Networks（管道网络）功能，在水动力建模圈内引发了广泛关注。这并不是一个简单的功能堆砌 ...
A little over a year ago, the U.S. Army Corps of Engineers’ Hydrologic Engineering Center (HEC) quietly launched new software that provides a whole new way of visualizing river analysis. This new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results